EyePoint Pharmaceuticals, Inc. Stock Analysis & AI Score
EyePoint Pharmaceuticals, Inc. (EYPT) has an ST Score of 24.1 (D+), driven by its Forecast (B+) and held back by its Momentum (F). Analysts rate it Buy with a $11.21 price target (+2666.5% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AIEYPT Stock Price History
EYPT Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
EYPT Latest Stock News
ST Score
EyePoint Pharmaceuticals, Inc. (EYPT) has an ST Score of 24.1 (D+), driven by its Forecast (B+) and held back by its Momentum (F). Analysts rate it Buy with a $11.21 price target (+2666.5% upside).
- Strongest
- ForecastB+
- Weakest
- MomentumF
All factor grades
- ForecastB+
- GrowthC-
- Financial StrengthD+
- ValuationD
- ProfitabilityF
- MomentumF
- Piotroski2/9
Press Releases
Company Contact Details
EYPT stock: frequently asked questions
What is EYPT's ST Score?
EyePoint Pharmaceuticals, Inc. (EYPT) has an ST Score of 24.1 (D+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is EYPT a buy, hold, or sell?
Analysts rate EYPT a Buy, with a price target of $11.21 (+2666.5% vs the current price). Our ST Score grades it D+ (24.1/100). The ST Score is a data-driven signal, not a recommendation.
What are EYPT's factor grades?
Valuation D, Profitability F, Financial Strength D+, Momentum F, Growth C-, Forecast B+.
What is EYPT's valuation grade?
EyePoint Pharmaceuticals, Inc. (EYPT) earns a valuation grade of D, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is EYPT's growth grade?
EyePoint Pharmaceuticals, Inc. (EYPT) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is EYPT's profitability grade?
EyePoint Pharmaceuticals, Inc. (EYPT) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is EYPT's financial strength grade?
EyePoint Pharmaceuticals, Inc. (EYPT) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for EYPT?
The average analyst price target for EyePoint Pharmaceuticals, Inc. (EYPT) is $11.21 from 20 analysts, which is +2666.5% versus the recent price of $0.41.
What is EYPT's Piotroski score?
EyePoint Pharmaceuticals, Inc. (EYPT) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.